University of South Florida

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Louisiana State University and Agricultural & Mechanical College

The University of Arizona

The Scripps Research Institute

Modulation Therapeutics

Hide & Seek Technologies, Inc.

Other

Exxon Chemical Patents, Inc.

Mark L McLaughlin

David L Morse

Lori Hazlehurst

Amod A Sarnaik

Robert P Hammer

Robert J Gillies

Josef Vagner

Shari Pilon-Thomas

Amanda Huynh

Michael Doligalski

Jerry R Smith

Christoph Rader

Thomas Scott Yokum

Frederick M Enright

William S Dalton

Hilary Sue Lackritz

J Bradford Merry

Priyesh Jain

Philip H Elzer

Xiuling Li

Hao Liu

David A Young

Alan F List

Yanwen Fu

Sheng Wei

Scott Antonia

Tod J Miller

Haibin Tian

Karl R Schneck, Jr

James Weldon

John A Jung

Calvin L Becker

Disclosed are compositions and methods for ex vivo expansion of tumor infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

Tumor-infiltrating lymphocytes for adoptive cell therapy

The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target (X) R and their use in the treatment of cancer.

Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer

Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.

Cyclic peptide compounds and methods of use thereof

Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only &#x2212;&#xbd; the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Toll-like receptor 2 ligands and methods of making and using thereof

Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.

TLR9 targeted therapeutics

The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).

Cyclic peptide conjugates and methods of use

The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.

Stabilized peptoid-peptide hybrids and uses thereof

The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.

Conjugates for immunotherapy

The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.

Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Integrin interaction inhibitors for the treatment of cancer

Growing community of inventors

Baton Rouge, LA, United States of America

Mark L McLaughlin